Inclusion Criteria:

- Written informed consent prior to any study related procedures

- Proven prostate cancer in need for endocrine treatment, except for neoadjuvant
hormonal therapy, but including patients with a rising PSA further to prostatectomy
or radiotherapy

- ECOG score to be equal to or above 2

- Testosterone level within age-specific normal range

- PSA value equal to or above 2 ng/ml

- Life expectancy of at least 6 months

Exclusion Criteria:

- Previous or current hormonal treatment of prostate cancer

- Recent or current treatment with any drugs modifying the testosterone level

- Candidate for curative treatment such as prostatectomy or radiotherapy

- History of severe asthma, anaphylactic reactions, angioedema, angioneurotic oedema or
Quincke's Oedema

- Hypersensitivity towards any component of degarelix or mannitol

- Cancer disease within the last 5 years except for prostate cancer and some skin
cancers

- Signs of liver impairment shown as elevated serum ALT or serum bilirubin

- Known hepatic disease

- Other laboratory abnormalities that judged by the investigator would interfere with
the patients participation in the trial or the evaluation of the trial results

- Clinically significant disorder including excessive alcohol or drug abuse that may
interfere with trial participation or influence the conclusion of the trial as judged
by the investigator

- Mental incapacity or language barrier precluding adequate understanding or
cooperation

- Having received an investigational product within the last 12 weeks preceding the
trial

- Previous participation in this trial